Thomas Maduskuie

Species-Specific Metabolism of SGX523 by Aldehyde Oxidase and the Toxicological Implications

Sharon Diamond, Jason Boer, Thomas Maduskuie et al. · Drug Metabolism and Disposition · 2010 · 138 citations

Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles

Victor G. Matassa, Thomas Maduskuie, Howard S. Shapiro et al. · Journal of Medicinal Chemistry · 1990 · 78 citations

Altmetric Attention Score, Peptidoleukotriene Antagonists, Organic Chemistry +18

Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans

Mingxin Qian, Stephen A. Bai, Bernice L. Brogdon et al. · Drug Metabolism and Disposition · 2007 · 50 citations

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies

Matthew C. Stubbs, Timothy C. Burn, Richard Sparks et al. · Clinical Cancer Research · 2018 · 49 citations

INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ)

Eddy W. Yue, Yunlong Li, Brent Douty et al. · ACS Medicinal Chemistry Letters · 2019 · 47 citations · Full text